Study Week	Week 0 (-≤4 weeks)	Wk 0	Wk 2* (+/- 2 days)	Wk 6* (+/- 2 days)	Wk 12*	Wk 14* (+/-1 week)	Wk 22* (+/-1 week)	Wk 24*	Wk 30* (+/-1 week)	Wk 36*	Wk 38* (+/-1 week)	Wk 46* (+/-1 week)	Wk 48*	Wk 60*	Wk 72*	Wk 84*	Wk 96*
Study Phase	**Screening**	**Baseline**	**Interventional**											**Observational**			
Assessment / Procedure																	
Study Treatment - INFLIXIMAB		X	X	X		X	X		X		X	X					
Informed Consent & Registration	X																
Inclusion/exclusion	X																
Randomisation		X															
Demographic data	X																
Medical & recent surgical history	X																
Pregnancy test (urine)	X																
Chest X-ray[1] & 12-lead ECG	X																
TB[1] and Hepatitis B&C Screening	X																
Urinalysis	X																
Immunoglobulins	X																
Serological test (RF, ACPA, ANA and anti-dsDNA)	X												X				
Haematology test (FBC); Blood chemistry (U&E, LFT); CRP and ESR	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Glucose & Lipid profile		X						X					X				
Unplanned surgery details					X			X		X			X				
Concomitant medication	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
Physical examination & Vital signs	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
28 Joint count (tender & swollen)	X	X			X			X		X			X	X	X	X	X
Assessment of General Health VAS		X			X			X		X			X	X	X	X	X
Global Assessment of Arthritis VAS	X	X			X			X		X			X	X	X	X	X
Global Assessment of Pain VAS		X			X			X		X			X	X	X	X	X
Physician global VAS	X	X			X			X		X			X	X	X	X	X
Morning stiffness (minutes)	X	X			X			X		X			X	X	X	X	X
HAQ-DI		X			X			X		X			X	X	X	X	X
RAQoL		X			X			X		X			X				
HADS		X			X			X		X			X				
EQ-5D		X			X			X		X			X				
Health Utilities Index		X			X			X		X			X				
Health, Social Care Use & Expenditure					X			X		X			X				
Inpatient/Outpatient Hospital Form					X			X		X			X				
Dorsal-Posterior X-ray hands & feet[3]		X											X				
Bone densitometry scan[3]		X											X				
Optional Biobank Samples		X	X[2]		X			X		X			X				
Adverse events		Monitor during trial treatment															

* If a time delay between randomisation and first dose of protocol treatment occurs, this should be accounted for when arranging the clinical assessment visits during the interventional (weeks 12, 24, 36 and 48) and the observational (weeks 60, 72, 84 and 96) phases of the study i.e. the week 12 visit should be scheduled 12 weeks after the participant's first dose of protocol treatment; if, for example, a participant's first treatment is delayed by 4 weeks, then all subsequent clinical assessment visits will be scheduled from the date of randomisation +4 weeks, e.g. their week 12 visit will be at week 16 (12 weeks + 4 weeks), to ensure all participants receive equal drug exposure despite treatment delays.

[1] Assessment need only be repeated if they have not been performed in the 24 weeks prior to screening.

[2] 5ml serum only to be collected at week 2.

[3] These procedures are to be performed at sites with specialist facilities only. Assessments undertaken up to 6 months prior to baseline or 6 weeks after the baseline visit is permissible.